IsoVax Therapeutics

IsoVax Therapeutics is a biotechnology company developing a transformative platform for isotype-specific vaccines, with a primary focus on IgE-mediated allergic diseases. The company's proprietary technology targets the M1' domain of membrane-bound IgE, enabling the selective depletion of IgE-switched B cells and plasma cells. This mechanism aims to halt the production of harmful IgE antibodies at the source, offering a potential long-term cure for severe allergies, including peanut allergy and asthma. IsoVax's approach differentiates itself from current treatments by targeting the immune system's memory of the allergy rather than just neutralizing circulating antibodies. The company is led by experts in IgE biology, including the original discoverers of the anti-IgE therapeutic class. Currently in the pre-clinical stage, IsoVax is advancing its lead candidates toward human clinical trials to address significant unmet needs in immunology.